PDB32 ECONOMIC EVALUATION OF RANIBIZUMAB FOR THE TREATMENT OF DIABETIC MACULAR EDEMA IN CANADA  by Haig, J. et al.
PDB27
COST-EFFECTIVENESS ANALYSIS OF METFORMIN COMBINED WITH
SAXAGLIPTIN VERSUS METFORMIN COMBINED WITH SULFONYLUREAS IN
TYPE-2 DIABETES PATIENTS IN CHILE
Elgart J1, Caporale J2, Aiello EC3, Waschbusch M3, Jotimliansky L3, Gagliardino JJ4,
Valencia JE5
1National University of La Plata, La Plata, Buenos Aires, Argentina, 2Institute for Clinical
Effectiveness and Health Policy, Buenos Aires, Argentina, 3Bristol-Myers Squibb, Buenos Aires,
Argentina, 4CENEXA, La Plata, Buenos Aires, Argentina, 5Bristol-Myers Squibb, Bogota,
Colombia
OBJECTIVES: To determine the cost-effectiveness relation of adding Saxagliptin to
Metformin therapy (SAXAMET) compared to adding Sulfonylureas (SULFMET),
in patientswith type 2 diabetesmellitus (DM2)whohave failed to achieve adequate
glycemic control with metformin. METHODS: A discrete event simulation model
(Cardiff long term cost-utilitymodel) with a fixed time increase based on UKPDS 68
was used to simulate disease progression and to obtain an estimate of the treat-
ment’s economic and health consequences in DM2 patients. Clinical efficacy pa-
rameters for Saxagliptin were obtained from the literature; drug acquisition costs,
adverse events (AEs) and microvascular and macrovascular complications were
taken into account. The time horizon was 20 years and the perspective was that of
the public health care system in Chile. Costs were expressed in US dollars (2009),
with an annual 3.5% discount. RESULTS: A lower number of non-fatal events were
found for the SAXAMET-treated group versus the SULFMET-treated group. Ad-
ditionally, the model predicted a lower number of fatal macrovascular (132.3 vs.
136.0) andmicrovascular (19.6 vs. 19.7) events for the SAXAMET-treated group vs.
the SULFMET-treated group. The total cost of the SAXAMET cohort was lower
than the SULFMET cohort: US$ 15.006.011 andU$S 14.557.581, respectively. Treat-
ment with SAXAMET resulted in a higher number of QALYs (9,794 vs. 9,594) and
LYs (23,068 vs. 23,019) for the 1000 patients’ cohort than treatmentwith SULFMET;
the incremental analysis per QALY and LY gained was -US$2,243 and US$ 9,182
respectively (dominant). CONCLUSIONS: Results suggest that the addition of Saxa-
gliptin to metformin therapy is dominant compared to the addition of sulfonyl-
ureas; therefore, this intervention would represent an efficient use of health re-
sources for DM2 patients in Chile.
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COST SAVINGS IN TYPE-2 DIABETES (T2D) WITH INSULIN GLARGINE
COMPARED WITH INSULIN DETEMIR IN THE UNITED KINGDOM
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OBJECTIVES: The objective was to determine whether the use of insulin glargine
(IG, Lantus) could result in cost savings in comparison with insulin detemir (ID,
Levemir) in T2D patients in the UK. METHODS: Clinical data for the analysis was
taken from a 1 year multi-national study (Rosenstock 2008) in 582 insulin-naïve
patients treated with IG or ID as add-on therapy to oral glucose lowering drugs. IG
was administered once daily in linewith it’s licence and ID once (44% of patients) or
twice daily (55%) according to treatment response. Mean daily insulin doses were
40U for IG and 71U for ID. Baseline characteristics were comparable on study entry.
After 1 year glycaemic control, weight gain, adverse events and risk of hypoglycae-
mia were similar for both groups so a cost minimisation analysis was undertaken.
Costs were calculated from a UK NHS perspective using MIMS November 2010
prices. Insulin cost was based on IG SoloStar and ID FlexPen prefilled disposable
injection devices, which are of similar cost. It was assumed that a new needle,
lancet and blood glucose test strip were used for each injection with a 2U priming
dose of insulin before each injection. RESULTS: The annual cost per patient for
needleswas £43 for IG and £66 for ID. The cost of lancets and test stripswas £122 for
IG and £190 for ID. The annual cost of insulin was £426 for IG and £758 for ID. The
total annual cost per patient of administering IGwas £591 comparedwith £1014 for
ID. Sensitivity analyses for weight gain, IG device and insulin dose confirmed the
robustness of the base case results. CONCLUSIONS: IG may represent a more cost
effective option for T2D patients in theUK requiring basal insulin analogue therapy
with potential annual cost savings of 42% (£423/patient) compared with ID.
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OBJECTIVES: Hypoglycemia is a common treatment related side effect of diabetes,
which can be associated with frequent emergency room use and hospitalization.
The objective of this study was to assess the direct medical costs of individual
hypoglycemia events in a US population of type 2 diabetes. METHODS: Patients
18 years with type 2 diabetes diagnosed during the period 2003 to 2008 were
selected from the MarketScan® Research Databases and followed from their first
diabetes diagnosis in the study period until the end of continuous coverage or
December 31, 2008, whichever came first. All individual hypoglycemia events iden-
tified by a claim (ICD-9-CM 250.3, 250.8, 251.0, 251.1, 251.2) on a unique date were
counted for each patient. Direct medical costs were calculated per hypoglycemia
event by treatment setting and diabetes drug regimen. RESULTS: A total of 2.4
million diabetes patients were selected. During follow-up, 91,595 of these patients
experienced 169,248 hypoglycemia events. Costs were highest for hypoglycemia
events identified in the emergency room (ER)-to-inpatient setting ($10,362/event),
followed by inpatient ($7,317/event), ER ($701/event), and outpatient ($285/event)
settings. Patients treated with an insulin only regimen had the highest direct med-
ical costs of hypoglycemia ($9.49 per patient per month). Among patients treated
with non-insulin regimens, the estimated hypoglycemia costs for patients on sul-
fonylureas were $3.87 per patient per month and $0.84 for other OADs.
CONCLUSIONS: Direct medical costs associated with hypoglycemia among type 2
diabetes patients varied by treatment setting and drug regimen. Patients treated
with insulin had the highest direct medical costs. Within non-insulin regimens,
patients on sulfonylureas had higher costs than those on non-sulfonylurea OADs.
Treatment strategies that provide effective glycemic control, with a lower potential
for inducing hypoglycemia should be considered in the management of type 2
diabetes.
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OBJECTIVES: The study assessed the economic burden incurred by type 2 diabetes
mellitus (T2DM) patients with oral anti-diabetic drugs (OADs) therapy in China.
METHODS: A cross-sectional survey was conducted between Dec 3rd, 2008 and July
31st, 2009 at 75 urban hospitals in 9 cities in China. A total of 9577 T2DM patients
with OADs therapy completed the self-administered questionnaires during their
clinical visits. The information collected from questionnaire included demo-
graphic characteristics, utilization of OADs, glycemic control, diabetes complica-
tions, annual direct medical costs and productivity lost associated with T2DM.
RESULTS:Themean age (SD)was 59.512.7 years, 51.1%weremale and themean
diabetes duration (SD) was 7.96.3 years. Only 7.9% and 15.3% of the patients
achieved HbA1c6.5%, and HbA1c7.0% respectively. The average total medical
expenditures was CNY 9127.2 per year, of which CNY 6478.5 was spent on T2DM.
The annual expenditure of OADs was CNY 4279.4, accounting for 66.1% of the total
annual T2DM treatment expenditure. The annual average diabetes-related costs
for outpatient and hospitalization were CNY 5998.9 and 4265.8 respectively. T2DM
patients diagnosed less than 3 years, 3-5 years, 5-10 years and more than 10 years
had an annual average treatment cost of CNY 4783.0, 5829.5, 6248.4, and 8183.8
respectively. The average annual productivity lost due to T2DM was 29.9 working
days. It resulted in an estimated average opportunity cost of CNY 2367.1 per capita
(The 2008 average annual income of urban residents was CNY 28898). The direct
treatment cost of T2DM and opportunity cost together accounted for 56% of pa-
tients’ disposable income in 2008 (CNY 15781). CONCLUSIONS: The study demon-
strated the high economic burden and inadequate glucose control among T2DM
patients with OADs therapy. The direct medical cost of T2DM increases with dis-
ease progression. It highlights the importance of implementing cost-effective ther-
apeutic regimens to improve diabetes management.
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OBJECTIVES: (1) To identify and analyse the benefits and costs of sponsored clinical
trials in a publicly funded New Zealand hospital, from the perspective of (a) the
research unit and (b) the district health board; (2) To identify patterns of costs and
benefits during the pre-trial, trial and follow-up stages of a clinical trial.METHODS:
We draw on the data relating to cases and controls in a health outcomes study of
two phase III clinical trials to assess preventative medication for patients at risk of
serious cardiovascular events. The data includeMinistry of Health data, The Centre
for Clinical Research and Effective Practice (CCRep) profit and loss statements,
CountiesManukauDistrict Health Board (CMDHB) Chronic CareManagement data,
trial protocols and data from a trial health outcome co-study. We identify patterns
of costs and benefits during the enrolment, trial and follow-up stages of a clinical
trial. RESULTS: The research unit and the health board both derive economic ben-
efits from these trials. The magnitude of the benefits differs depending on the
perspective taken. The research unit has total economic benefits ranging from
US$470 and US$846 per participant which it is able to reinvest into other research
projects. We find the benefits from the perspective of the health board are positive
but small US $15 - $45 per participant over the eight year period. Savings from
treatment cost avoidance are lower than anticipated. We find two periods where
costs are highest (1) during enrolment and (2) at the end of the trial.CONCLUSIONS:
There may be economic advantages in actively encouraging sponsored clinical
trials within New Zealand publically funded hospitals. This study provides evi-
dence of differing patterns of costs and benefits during the three stages of a clinical
trial – enrolment, trial and follow-up.
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OBJECTIVES: Diabetic macular edema (DME) is an ophthalmologic complication
that develops in a subset of patients with diabetic retinopathy and that causes loss
of functionality, reduced health-related quality of life, visual impairment, and if
left untreated, blindness. A cost-effectiveness analysis was conducted to measure
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and compare the economic costs and clinical outcomes associated with ranibi-
zumabmonotherapy versus laser photocoagulation alone for the treatment of DME
in Canada. METHODS: Cost-effectiveness of ranibizumab to a Canadian healthcare
systemwas analyzed using aMarkovmodel based on data from the RESTORE clinical
trial. After one year of treatment, the RESTORE trial reported a 6.1 (p0.0001) letter
improvement in best corrected visual acuity (BCVA) with ranibizumab compared to
laser photocoagulation. The model included 8 health states as defined by BCVA, and
followed a cohort of 63 year old patients with DME due to either type 1 or type 2
diabetes over a timehorizon to amaximumof 20 years. Year 1 health state transitions
andallhealthstateutilitieswerederived fromtheRESTOREtrial. Fromyear2onwards,
health state transitions were based on fixed probabilities of improving or worsening
BCVA. Resource use and costs were collected from the RESTORE trial, published liter-
ature, or standard Canadian sources. RESULTS: Compared to laser photocoagula-
tion, patients receiving ranibizumabmonotherapy accrued an additional 1.44 years
without legal blindness (BCVA 35 letters). Also, patients receiving ranibizumab
accrued an additional 0.19 quality-adjusted life years (QALYs) with a total incre-
mental cost of approximately $8,500, resulting in approximately $44,000 per QALY
gained. CONCLUSIONS: Compared to laser photocoagulation, ranibizumab mono-
therapy shows cost-effectiveness within commonly accepted cost per QALY
thresholds. In addition, this analysis predicts the use of ranibizumab for DME will
result in more years without legal blindness.
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OBJECTIVES: To evaluate the long-term health and economic outcomes of Insulin
Detemir (IDet) therapy in uncontrolled patients with type 2 diabetes mellitus
(T2DM) switching from insulin Glargine (IGlar) in the Chinese setting. METHODS:
Thepublished and validatedCOREDiabetesModelwas used tomake the long- term
(30 years) projection of health economic outcomes. The patient demographic in-
formation and clinical endpoints were derived from South Korea sub-analysis of
the PREDICTIVE trial. The study was a large, multi-centre, 6 months observational
study assessing the safety and efficacy of IDet. HbA1c was reduced of 0.2 %
(p0.05) by switching from IGlar to IDet. Baseline risk factors and racial character-
istic data were obtained from Chinese cohort studies. The market retail prices of
medications were calculated to estimate treatment costs. The diabetes manage-
ment and complications costs were obtained from Chinese published data and
adjusted to 2010 values using the Chinese Consumer Price Index. An annual dis-
counting rate of 3% was used for both health and economic outcomes. One-way
sensitivities analysis was performed. RESULTS: The treatment of IDet converted
from IGlar was projected to reduce the cumulative incidences of DM-related com-
plications. Background retinopathy, end-stage renal disease, ulcer, myocardial in-
farction events were reduced 0.685%,0.167%,0.243%,0.482% respectively. Therapy
conversion to IDet was projected to improve life expectancy by 0.061 year, and was
associated with improvements of 0.484 quality adjusted life year (QALY). The costs
of complicationswere reduced by CNY 5,595, resulting in a total directmedical cost
saving of CNY 2,869. CONCLUSIONS: Therapy conversion from IGlar to IDet in
T2DM patients could delay the onset of diabetes complications, was associated
with improvements in life expectancy and QALYs, and reduced direct cost over
patient lifetimes. IDet was shown to be a dominant treatment option in patients
with T2DM inadequately controlled with IGlar in Chinese setting.
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OBJECTIVES: The aim of this research was to assess the cost-effectiveness of phar-
maceutical care (PC) programme (relative to control) for patients with type 2 DM.
METHODS: A total of 222 patients were recruited at a pharmacist-managed diabe-
tes clinic of a government hospital in Malaysia and randomly allocated to inter-
vention and control group. Patients in the intervention group (n  111) were pro-
vided with PC, whereas, patients in the control group (n  111) received only the
usual pharmacy service. Clinical and economic outcomes of patients were evalu-
ated at baseline and after six months. RESULTS: There was no significant differ-
ence in the demographic and clinical characteristics at baseline between the inter-
vention and the control group. Significant reduction in glycosylated haemoglobin
(HbA1c) was observed frombaseline to 6-month in the intervention group. (Mean
standard deviations  9.93  1.76% versus 8.83  1.85%, p  0.05). Although the
total costs per patient were significantly higher for the intervention group
(RM681.07 versus RM542.64; p 0.014), the cost effectiveness ratio was lower in the
intervention group (RM619.15 versus RM3617.60/1% reduction in HbA1c). The in-
cremental cost-effectiveness ratio for HbA1c was RM145.72/%. CONCLUSIONS: In
conclusion, incorporation of PC into the management of type 2 DM can have a
definitive, positive impact on glycaemic control and lead to more cost-effective
treatment.
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OBJECTIVES: Physicians, Nursing Care Managers (CMs) and Dieticians are part of
the healthcare team looking after patients with diabetes mellitus at the 9 public
sector primary care clinics in the National Healthcare Group (NHG) in Singapore.
This paper studies the association between the level of glycaemic control and the
utilization of these professional services by type 2 diabetes mellitus (T2DM) pa-
tients at these clinics.METHODS: This study included all patients with T2DMwho
had attended the same clinics in 2009 for at least 12 months for the treatment of
diabetes. Data was extracted from the NHG Diabetes Registry (CDMS). The number
of outpatient clinic visits to the Physicians, CMs and Dieticians in a year was com-
pared by age and degree of glycaemic control using the mean glycated haemoglo-
bin (HbA1c) for the year, “Optimal” being 7%, “Acceptable” 7-9% and “Poor” 9%.
RESULTS: There were 58,057 T2DM patients with more females (54%) and dispro-
portionately more Indians (13%) and fewer Chinese (71%) than the general popula-
tion. Mean HbA1c was 7.421.27% which decreased gradually with age from 8.16%
(40 years) to 6.86% (90 years). The annual Physician attendances for diabetes
consult increased from 4.11.5 (“Optimal” HbA1c control) to 5.22.2 (“Poor” con-
trol), representing 85-89% of all Physician attendances for the year. Proportion of
patients seen by the CMs increased from 6.8% (“Optimal” control) to 52.5% (“Poor”
control), and similar for Dieticians, an increase from 1.3% (“Optimal” control) to
9.5% (“Poor” control). CONCLUSIONS: T2DM patients with “Optimal” glycaemic
control had significantly fewer clinic visits to the healthcare team than those with
“Poor” control, translating to lower overall healthcare costs for the patients and the
healthcare system. More attention is needed to improve the care of the patients
with “Poor” glycaemic control, in order to achieve better long-term health out-
comes and reduce healthcare utilization and costs.
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OBJECTIVES: Quick release (QR)-bromocriptine mesylate is a new treatment for
type 2 diabetes (T2DM) that has been shown to reduce HbA1c and cardiovascular
(CV)-related hospitalizations over one year. The objective of this study was to es-
timate the economic impact of (QR)-bromocriptine versus other oral antidiabetic
drugs as add-on therapy for patients who failed initial treatment. METHODS: A
decision-analysis model was designed to compare outcomes among QR-bro-
mocriptine, pioglitazone, rosiglitazone, and sitagliptin over one year when used as
add-on therapy. For each drug, changes in HbA1c levels were derived from product
labels and used to derive the expected number of hospitalizations for diabetes-
related complications based on published equations linking HbA1c levels to hos-
pitalizations. Rates of CV-related events (major adverse cardiac events, congestive
heart failure, angina, and revascularization) were extracted from clinical trial re-
ports of antidiabetic drugs in T2DM and were expressed on an annualized basis.
Hospital costs per admission were estimated from the Healthcare Cost & Utiliza-
tion Project, while drug costs were based on wholesale acquisition cost. A payer
perspective was assumed and direct medical costs were expressed in 2009 USD.
RESULTS: Patients treated with QR-bromocriptine had lower diabetes-related hos-
pitalization costs ($2,017) than those receiving rosiglitazone ($2,038), and higher
costs compared to pioglitazone ($1,928) and sitagliptin ($1,989). Patients receiving
QR-bromocriptine had lower CV-related hospitalization costs ($426) than those
treated pioglitazone, sitagliptin, or rosiglitazone ($523, $708, and $729, respec-
tively). Annual drug costs were lower for patients receiving QR-bromocriptine
($2,122) compared to pioglitazone ($2,605) and sitagliptin ($2,282) and higher than
for those receiving rosiglitazone ($1,977). Overall one-year costs were estimated to
be $4,565, $5,056, $4,979, and $4,745 for QR-bromocriptine, pioglitazone, sitagliptin,
and rosiglitazone respectively. CONCLUSIONS: Our findings suggest that, over one
year, T2DM patients treated with QR-bromocriptine as an add-on therapy are ex-
pected to have lower costs than those receiving pioglitazone, sitagliptin, and
rosiglitazone.
Diabetes/Endocrine Disorders – Patient-Reported Outcomes & Preference-Based
Studies
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MAIL-ORDER PHARMACY USE AND MEDICATION ADHERENCE AMONG
MEDICARE PART D BENEFICIARIES WITH DIABETES
Zhang L, Zakharyan A, Stockl KM, Harada AS, Curtis BS, Solow BK
Prescription Solutions, Irvine, CA, USA
OBJECTIVES: To examinemedication adherence amongMedicare Part D beneficia-
ries with diabetes and explore whether there is any association of usingmail-order
pharmacy (vs. retail pharmacy) with better adherence in this patient population.
METHODS:Using administrative pharmacy claims data, we conducted a retrospec-
tive cohort study on the Medicare Part D beneficiaries who newly initiated oral
anti-diabetic treatment between July 1, 2008 and December 31, 2008. The primary
outcome of interest was medication adherence to oral anti-diabetics during the
benefit year of 2009, which was measured using the proportion of days covered
(PDC). Mail-order pharmacy users were matched to retail pharmacy users via pro-
pensity scoring, controlling for patient’s demographic and clinical characteristics.
RESULTS: A total of 22,546 patients with diabetes were identified. The average PDC
was 0.60 and only 41.6% of the study populationwas adherent (defined as PDC0.8)
with oral anti-diabetic medications during calendar year 2009. The matched sam-
ple included 1361 patients from each cohort. Compared with the retail pharmacy
A97V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 1 – A 2 1 4
